Business, energy, technology, markets and global industry news from Business News Today

mRNA therapy

PharmaDeviceNews mRNA therapy
Representative image: Laboratory research into EXG-7001 highlights Nippon Shinyaku and Elixirgen Therapeutics’ effort to develop a full-length dystrophin mRNA therapy for Duchenne muscular dystrophy.
Pharma & Biotech

Nippon Shinyaku backs EXG-7001 as full-length dystrophin mRNA strategy enters Duchenne race

Discover how Nippon Shinyaku’s EXG-7001 option could advance full-length dystrophin mRNA therapy for Duchenne muscular dystrophy.

Read More
Representative image of researchers working in a modern cell therapy laboratory, reflecting T-CURX’s acquisition of Pantherna Therapeutics and the growing race to advance in vivo CAR-T, mRNA delivery and lipid nanoparticle technologies.
Pharma & Biotech

Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing

T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.

Read More
Pharma & Biotech

CREATE’s in vivo CAR-T achieves full B cell depletion and repeat dosing in primates

CREATE Medicines shows redosable B cell depletion in primates with in vivo CAR-T platform. Find out what this means for autoimmune and oncology therapy.

Read More